News

People with Sjögren’s syndrome and other systemic autoimmune rheumatic diseases (SARDs) may be at a greater risk of severe complications from COVID-19 than people without these disorders, a study reports. Specifically, SARDs patients are more likely to develop venous thromboembolism (VTE), or blood clots in…

RSLV-132, an investigational treatment for autoimmune conditions, led to significant and clinically meaningful reductions in patient-reported fatigue in people with primary Sjögren’s syndrome, results from a Phase 2 clinical trial show.

Primary Sjogren’s syndrome (pSS) patients have less diversity in their gut microbiome — with less abundant beneficial bacteria but more abundant opportunistic bacteria with pro-inflammatory activity — compared with healthy people, a study suggests. Patients also had higher levels of pro-inflammatory immune signaling molecules, which were…

Applications for a next round of Sjögren’s Foundation research grants are being accepted from U.S. investigators working to better understand Sjögren’s syndrome, a chronic immune system disorder, and improve patients’ lives. The one-year grants are available to basic and clinical scientists who hold an advanced degree at a U.S.

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient populations. The initiative seeks to extend the reach of clinical studies to underserved populations in the nation’s urban and rural…

Primary Sjögren’s syndrome (pSS) syndrome can be classified based on the extent of organ involvement, fatigue, and pain, with symptoms varying substantially from patient to patient, a new study reports. The study, “Burden of illness among subgroups of patients with primary Sjögren’s syndrome and systemic involvement,”…

Wize Pharma‘s LO2A eye drops result in clinically meaningful improvements in dry eye signs and symptoms in people with Sjögren’s syndrome, topline results from an exploratory Phase 4 trial show. The treatment continued to demonstrate a good safety profile, and was found to be at least as…

Long-term use of hydroxychloroquine significantly lowers the risk of coronary artery disease, the most common form of heart disease, in people with Sjögren’s syndrome, a data study in Taiwan suggested. Its cardiovascular protective effects, in addition to a wider range of benefits, suggest the medication may control…

An immune regulatory molecule known as NEAT1 is produced at greater levels in the immune T-cells of people with primary Sjogren’s syndrome, and these levels seem to correlate with disease duration, a study has found. The findings suggest that NEAT1 may be used as a new…

Using the PI3K-delta inhibitor seletalisib as an add-on to standard treatment showed a trend toward easing disease activity and  dryness, and significantly lowered patient-reported fatigue in people with primary Sjögren’s syndrome (pSS), according to data from a Phase 2 trial. Findings from this proof-of-concept study (NCT02610543) —…